Research ArticleDrug Discovery and Translational Medicine
ONO-8590580, a Novel GABAA α5 Negative Allosteric Modulator Enhances Long-Term Potentiation and Improves Cognitive Deficits in Preclinical Models
Soichi Kawaharada, Miki Nakanishi, Nobuto Nakanishi, Keisuke Hazama, Masato Higashino, Tetsuya Yasuhiro, Arwel Lewis, Gary S. Clark, Mark S. Chambers, Scott A. Maidment, Seishi Katsumata and Shuji Kaneko
Journal of Pharmacology and Experimental Therapeutics July 2018, 366 (1) 58-65; DOI: https://doi.org/10.1124/jpet.117.247627
Soichi Kawaharada
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Miki Nakanishi
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Nobuto Nakanishi
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Keisuke Hazama
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Masato Higashino
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Tetsuya Yasuhiro
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Arwel Lewis
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Gary S. Clark
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Mark S. Chambers
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Scott A. Maidment
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Seishi Katsumata
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Shuji Kaneko
Discovery Research Laboratories I (So.K., M.N., N.N., K.H., T.Y., Se.K.) and Medicinal Chemistry Research Laboratories (M.H.), ONO Pharmaceutical Co., Ltd., Shimamoto-cho, Mishima-gun, Osaka, Japan; Charles River Laboratories International, Inc., Saffron Walden, Essex, United Kingdom (A.L., G.S.C., M.S.C., S.A.M.); and Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan (So.K., Sh.K.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Effect of a Novel GABAA α5 NAM in Preclinical Models
Soichi Kawaharada, Miki Nakanishi, Nobuto Nakanishi, Keisuke Hazama, Masato Higashino, Tetsuya Yasuhiro, Arwel Lewis, Gary S. Clark, Mark S. Chambers, Scott A. Maidment, Seishi Katsumata and Shuji Kaneko
Journal of Pharmacology and Experimental Therapeutics July 1, 2018, 366 (1) 58-65; DOI: https://doi.org/10.1124/jpet.117.247627
Research ArticleDrug Discovery and Translational Medicine
Effect of a Novel GABAA α5 NAM in Preclinical Models
Soichi Kawaharada, Miki Nakanishi, Nobuto Nakanishi, Keisuke Hazama, Masato Higashino, Tetsuya Yasuhiro, Arwel Lewis, Gary S. Clark, Mark S. Chambers, Scott A. Maidment, Seishi Katsumata and Shuji Kaneko
Journal of Pharmacology and Experimental Therapeutics July 1, 2018, 366 (1) 58-65; DOI: https://doi.org/10.1124/jpet.117.247627
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement